AU677309B2 - Purification of factor VII - Google Patents

Purification of factor VII Download PDF

Info

Publication number
AU677309B2
AU677309B2 AU64239/94A AU6423994A AU677309B2 AU 677309 B2 AU677309 B2 AU 677309B2 AU 64239/94 A AU64239/94 A AU 64239/94A AU 6423994 A AU6423994 A AU 6423994A AU 677309 B2 AU677309 B2 AU 677309B2
Authority
AU
Australia
Prior art keywords
fvii
buffer
purification
naci
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64239/94A
Other languages
English (en)
Other versions
AU6423994A (en
Inventor
Tony Jorgensen
Anders Hjelholt Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU6423994A publication Critical patent/AU6423994A/en
Application granted granted Critical
Publication of AU677309B2 publication Critical patent/AU677309B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU64239/94A 1993-03-31 1994-03-24 Purification of factor VII Ceased AU677309B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK382/93 1993-03-31
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner
PCT/DK1994/000122 WO1994022905A1 (en) 1993-03-31 1994-03-24 Purification of factor vii

Publications (2)

Publication Number Publication Date
AU6423994A AU6423994A (en) 1994-10-24
AU677309B2 true AU677309B2 (en) 1997-04-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64239/94A Ceased AU677309B2 (en) 1993-03-31 1994-03-24 Purification of factor VII

Country Status (16)

Country Link
US (1) US5700914A (OSRAM)
EP (1) EP0691984A1 (OSRAM)
JP (1) JPH08508264A (OSRAM)
CN (1) CN1039231C (OSRAM)
AU (1) AU677309B2 (OSRAM)
CA (1) CA2159313A1 (OSRAM)
CZ (1) CZ253395A3 (OSRAM)
DK (1) DK38293D0 (OSRAM)
FI (1) FI954649A7 (OSRAM)
HU (1) HUT72712A (OSRAM)
IL (1) IL109164A0 (OSRAM)
NO (1) NO953883L (OSRAM)
PL (1) PL310887A1 (OSRAM)
TW (1) TW278079B (OSRAM)
WO (1) WO1994022905A1 (OSRAM)
ZA (1) ZA941956B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
JP4469933B2 (ja) † 1998-05-06 2010-06-02 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィによるタンパク質精製
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
RU2364626C2 (ru) * 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
BRPI0416950B8 (pt) 2003-12-01 2021-05-25 Novo Nordisk Healthcare Ag métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
MX2007007356A (es) * 2004-12-23 2007-08-14 Novo Nordisk Healthcare Ag Reduccion del contenido de contaminantes proteinicos en composiciones que comprenden una proteina dependiente de la vitamina k de interes.
PT1841863E (pt) * 2005-01-14 2010-10-25 Bayer Healthcare Llc Método para a purificação de factor vii
US20070129298A1 (en) * 2005-07-22 2007-06-07 Maxygen Holdings, Ltd. In-solution activation of factor vii
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (es) * 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
ES2906118T3 (es) 2016-12-22 2022-04-13 Km Biologics Co Ltd Método cromatográfico para recolectar factor VII de coagulación sanguínea con alto rendimiento

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
CN1121723A (zh) 1996-05-01
FI954649A0 (fi) 1995-09-29
NO953883D0 (no) 1995-09-29
NO953883L (no) 1995-11-28
HU9502846D0 (en) 1995-12-28
EP0691984A1 (en) 1996-01-17
CN1039231C (zh) 1998-07-22
HUT72712A (en) 1996-05-28
DK38293D0 (da) 1993-03-31
IL109164A0 (en) 1994-06-24
TW278079B (OSRAM) 1996-06-11
CZ253395A3 (en) 1996-01-17
PL310887A1 (en) 1996-01-08
CA2159313A1 (en) 1994-10-13
WO1994022905A1 (en) 1994-10-13
FI954649L (fi) 1995-09-29
FI954649A7 (fi) 1995-09-29
AU6423994A (en) 1994-10-24
JPH08508264A (ja) 1996-09-03
ZA941956B (en) 1994-09-30
US5700914A (en) 1997-12-23

Similar Documents

Publication Publication Date Title
AU677309B2 (en) Purification of factor VII
US5580560A (en) Modified factor VII/VIIa
ES2263199T3 (es) Analogos del factor x con un sitio de ruptura de proteasa modificado.
CA1339815C (en) Modified factor vii/viia
US5225537A (en) Methods for producing hybrid phospholipid-binding proteins
US5516650A (en) Production of activated protein C
IL88559A (en) Vectors and compounds for direct expression of human activated C protein
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
JP2001513632A (ja) Ｘ因子欠失突然変異体およびそのアナログ
Zhang et al. Role of the hexapeptide disulfide loop present in the. gamma.-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C
Morita et al. Calcium binding to a human factor IXa derivative lacking γ-carboxyglutamic acid: evidence for two high-affinity sites that do not involve β-hydroxyaspartic acid
EP0323149B1 (en) Vectors and compounds for expression of zymogen forms of human protein C
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
Yu et al. Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX
US6010844A (en) Methods of preparing and recovering proteins
WO1991012320A1 (en) Activated protein c with truncated light chain
NZ545825A (en) Plasminogen activators having reduced lysine binding capacity
Mollerup et al. The use of RP‐HPLC for measuring activation and cleavage of rFVIIA during purification
CZ328594A3 (en) PURIFICATION OF CRINGL-CONTAINING PEPTIDES, PARTICULARLY t-PA
AIS A zyxwvutsrqponmlkjihgfedcb
MXPA99007768A (en) Factor x analogues with a modified protease cleavage site
JP2001514516A (ja) 活性化ビタミンｋ依存性血液因子およびその製造方法
MXPA99007817A (en) Factor x deletion mutants and analogues thereof